June 12, 2025
BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal
BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine
FDA Approves UroGen’s Chemo-Turned-Gel Drug ZUSDURI Despite Negative Advisory Vote
UroGen; FDA approval; ZUSDURI; UGN-102; chemo-turned-gel drug; mitomycin gel; low-grade intermediate-risk non–muscle-invasive bladder cancer; negative AdComm vote; ENVISION trial; ODAC
FDA Launches AI Tool to Accelerate and Transform Drug Review Processes
FDA; AI tool; drug review; rapid review; generative AI; regulatory science; Elsa; automation; application assessment
Nuvation Bio Scores First FDA Approval for Oral Lung Cancer Drug Ibtrozi
Nuvation Bio; FDA approval; Ibtrozi; taletrectinib; lung cancer; ROS1-positive NSCLC; oral treatment; tyrosine kinase inhibitor
NVIDIA and Novo Nordisk Partner to Accelerate AI-Driven Drug Discovery
NVIDIA; Novo Nordisk; AI models; drug discovery; Gefion AI Supercomputer; BioNeMo; Omniverse; pharmaceutical innovation
Genentech Lays Off 143 Employees as Part of Ongoing Cuts by Roche in Bay Area
Genentech; Roche; layoffs; South San Francisco; biotech job cuts; Bay Area; AI strategy; WARN filing; pharmaceutical; biotech industry
FDA Leaders Anticipate Imminent Drug Approval Decisions
FDA; drug approval; PDUFA date; regulatory decision; upcoming approvals; FDA leadership
Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs
Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery